Business
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
FORT MYERS, Fla., January 12, 2026--NeoGenomics announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company’s Chief Financial Officer.
About this update from Neogenomics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2390,"height":984,"url":"https://media.zenfs.com/en/business-wire.com/3721aa7ec6c06ff32ec91950b999abb0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jiPwQSp3WaAEJ5XDqFCLEg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM5NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3721aa7ec6c06ff32ec91950b999abb0","width":960,"height":395},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Ec0Y8IKwpEZ42kvdoWfQQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05ODg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3721aa7ec6c06ff32ec91950b999abb0","width":1200,"height":494}},"lazy":false},{"type":"text","content":"– Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million –","length":135,"tagName":"p","attribs":{}},{"type":"text","content":"– Announces Chief Financial Officer transition –","length":48,"tagName":"p","attribs":{}},{"type":"text","content":"FORT MYERS, Fla., January 12, 2026--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company’s Chief Financial Officer.","length":312,"tagName":"p"},{"type":"text","content":"Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue","length":64,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"For the fourth quarter of 2025, NeoGenomics expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%.","length":149,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"For the full-year 2025, NeoGenomics expects to report total revenue of approximately $727 million, representing year-over-year growth of 10%.","length":141,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":290,"olType":false},{"type":"text","content":""Our preliminary fourth quarter revenue reflects our ongoing commitment to being the cancer testing ‘partner of choice’ to pathologists and oncologists in the community setting, where approximately 80% of cancer care is delivered today," stated Tony Zook, CEO of NeoGenomi...